Status:
COMPLETED
Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS)
Lead Sponsor:
TG Therapeutics, Inc.
Conditions:
Relapsing Multiple Sclerosis (RMS)
Eligibility:
All Genders
18-55 years
Phase:
PHASE3
Brief Summary
This study determines the Annualized Relapse Rate (ARR) in participants with RMS after 96 weeks (approximately 2 years) treatment with intravenous (IV) infusion of ublituximab/oral placebo compared to...
Eligibility Criteria
Inclusion
- Diagnosis of relapsing multiple sclerosis (RMS) (McDonald Criteria 2010)
- Active disease
- Expanded disability status scale (EDSS) 0 - 5.5 (inclusive) at screening
Exclusion
- Treatment with prior Anti-cluster of differentiate 20 (CD20) or other B cell directed treatment
- Treatment with the following therapies at any time prior to randomization: alemtuzumab, natalizumab, teriflunomide, leflunomide and Stem cell transplantation
- Diagnosed with primary progressive multiple sclerosis (PPMS)
- Pregnant or nursing
Key Trial Info
Start Date :
August 25 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 12 2020
Estimated Enrollment :
545 Patients enrolled
Trial Details
Trial ID
NCT03277248
Start Date
August 25 2017
End Date
November 12 2020
Last Update
December 6 2021
Active Locations (13)
Enter a location and click search to find clinical trials sorted by distance.
1
TG Therapeutics RMS Investigational Trial site
Phoenix, Arizona, United States, 58018
2
TG Therapeutics RMS Investigational Trial Site
Aurora, Colorado, United States, 80045
3
TG Therapeutics RMS Investigational Trial Site
Tampa, Florida, United States, 33612
4
TG Therapeutics RMS Investigational Trial Site
Lexington, Kentucky, United States, 40513